157156
Has tobacco control cut New York City African-American cancer death rates to below White levels everywhere except Utah and Hawaii?
Background. By 2003, New York City (NYC) African-American (AA) cancer death rates were below White levels everywhere except Utah and Hawaii. So I studied relationships between tobacco control and those cancer death rates and racial disparity reversals, using lung cancer death rates as a cumulative tobacco smoke damage (smoke load) bio-index. Methods. Published National Center for Health Statistics age-standardized death rates (rates) were used and male lung/all other cancer death rate linear regressions run. Results. 2003 NYC African-American male and female all sites cancer deaths per 100,000 reached 214 and 146, respectively, having dropped about 40% in males since 1981-1983, and reached female and male levels below and approaching NYC White levels, respectively. Tight NYC and United States White and AA male lung/other cancer death rate associations were seen (each p<0.05). Mayor Bloomberg's cigarette tax rises and public smoking bans were followed by 5%/year drops in NYC AA male cancer death rates. Discussion. Continuing lockstep changes in lung and other cancer death rates in NYC and US males suggest that smoking/tobacco control drives temporal and racial disparities in those death rates. Increasing tobacco taxes, smoke pollution bans, and smoking cessation help may help greatly decrease cancer death rates.
Learning Objectives: Describe racial cancer death rate trends in New York City and America.
Describe racial cancer death rate disparity trends in New York City and America.
Describe tobacco control/cancer death rate associations in New York City and America
Keywords: Tobacco Control, Health Disparities
Presenting author's disclosure statement:Any relevant financial relationships? No Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|